Lenabasum for skin disease in patients with diffuse cutaneous systemic sclerosis
This study is important because it exami nes the effects of cannabinoid (CB) modulation in SSc, a hitherto unexplored pathway, it uses the American College of Rheumatology (ACR) Combined Response Index in Systemic Sclerosis (CRISS) index as an outcome in a 12‐week as opposed to its intended use in 12‐month clinical trials, and it redem onstrates the utility of obtaining skin biopsies to assess secondary outcomes in SSc clinical trials.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Monique Hinchcliff Tags: EDITORIAL Source Type: research